Lilly  4Q Revenues: $19.3 billion +43% 4Q Earnings: $6.6 billion +50% FY Revenues: $65.2 billion +45%  FY Earnings: $20.6 billion +95% Comments: Growth in the quarter driven by a 46% increase in volume, partially offset by a 5% decrease due to lower realized prices. Key Products revenue grew to $13.8 billion in the quarter, led by Mounjaro and Zepbound.  Mounjaro sales were $7.4 billion in the quarter, up 110%. Zepbound sales were $4.3 billion, up 123%. Verzenio sales...